A rise in the geriatric population and unhealthy lifestyles are factors responsible for the rise in infectious diseases. Appendicitis occurs in 7% of the U.S. population with an incidence rate of 1.1 cases per 1000 people per year. Additionally, the rise in endocarditis is also associated with increased comorbid conditions, increased placement of medical devices, and injection drug use. The rate of endocarditis increases by approximately 4.1% per year in the European region and increases by 106% over a period of 18 years. Factors such as the rise in infectious diseases and several underlying conditions are expected to boost the adoption of effective diagnostic tools, fueling market growth.
Among all imaging modalities, nuclear medicine is showing promising results in the diagnosis of infectious diseases. It identifies crucial complementary information, allowing visualization of infectious pathophysiology beyond morphologic imaging. Numerous research activities are conducted using nuclear medicine techniques as the detection of metabolic abnormalities is done precisely by these techniques and it preceded morphological changes identified by structural imaging. Nuclear medicine techniques also show promising results in the diagnosis of COVID-19 infection. Thus, nuclear medicine holds a great growth opportunity as an identification tool in infection imaging.
Labeling of autologous leukocytes of purified neutrophils with In-111-oxine or 99m-Tc-HMPAO and imaging at variable time points to detect inflammatory bowel disease like Crohn’s disease and ulcerative colitis. Thus, the adoption of nuclear medicine is rapidly increasing among end users and researchers to effectively and quickly diagnose critical disease conditions. The increased use of PET/CT and PET/MRI is also influencing the industry’s growth. However, the outbreak of COVID-19 has led to a decline in diagnostic activities involving the detection of infectious diseases using imaging modalities and national lockdowns of universities and research institutes, halting numerous research activities in this space. This led to a decline in 2020.
U.S. Infection Imaging Services Market Report Highlights
- The acute appendicitis segment dominated the market for U.S. infection imaging services and accounted for the largest revenue share of 24.06% in 2021. It is further expected to continue its dominance over the forecast period
- The atherosclerosis segment is expected to register the fastest CAGR of 4.6% during the forecast period. The need for early and precise diagnosis for studying various diseases is expected to contribute to the growth of the segment
- Osteomyelitis shows nonspecific symptoms, and physical examination and laboratory results often delay identification. Techniques like unenhanced MRI can be used to identify tissue changes and the involvement of surrounding bones within two days of infection onset
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Indication
1.1.2. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.6.2. Volume price analysis (Model 2)
1.6.2.1. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1: Understanding the market dynamics
1.9.2. Objective 2: Understanding the market estimates and forecasts
1.9.3. Objective 3: Understanding the attributes such as strategy framework, competitor categorization
1.9.4. Objective 4: Understanding the key product and application scopes to conclude on the market size
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. U.S. Infection Imaging Services Market Variables, Trends & Scope
3.1. Market Lineage outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Product Pipeline Analysis, by Stage
3.4. Market Dynamics
3.4.1. Market Driver Analysis
3.4.1.1. Increasing prevalence of infectious diseases
3.4.1.2. Growing number of outpatient settings with imaging services
3.4.1.3. Growing awareness about medical imaging
3.4.2. Market Restraint Analysis
3.4.2.1. Radiation exposure
3.5. U.S. Infection Imaging Services: Market Analysis Tools
3.5.1. Industry Analysis - Porter’s
3.5.1.1. Supplier Power
3.5.1.2. Buyer Power
3.5.1.3. Substitution Threat
3.5.1.4. Threat from new entrant
3.5.1.5. Competitive rivalry
3.5.2. PESTEL Analysis
3.5.2.1. Political Landscape
3.5.2.2. Environmental Landscape
3.5.2.3. Social Landscape
3.5.2.4. Technology Landscape
3.5.2.5. Legal Landscape
3.5.3. Major Deals & Strategic Alliances Analysis
3.5.4. Covid-19 Impact Analysis
Chapter 4. U.S. Infection Imaging Services Market: Segment Analysis, by Indication, 2018 - 2030 (USD Million)
4.1. Definitions & Scope
4.2. Indication market share analysis, 2021 & 2030
4.3. Segment Dashboard
4.4. U.S. Infection Imaging Services Market, by indication, 2018 to 2030
4.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5.1. Fever of unknown origin
4.5.1.1. Nuclear Medicine
4.5.1.2. Others
4.5.2. Orthopedic Hardware
4.5.2.1. Nuclear Medicine
4.5.2.2. Others
4.5.3. Musculoskeletal infection
4.5.3.1. Nuclear Medicine
4.5.3.2. Others
4.5.4. Acute Appendicitis
4.5.4.1. Nuclear Medicine
4.5.4.2. Others
4.5.5. Osteomyelitis
4.5.5.1. Nuclear Medicine
4.5.5.2. Others
4.5.6. Systemic vasculitis
4.5.6.1. Nuclear Medicine
4.5.6.2. Others
4.5.7. Skin and soft tissue infection
4.5.7.1. Nuclear Medicine
4.5.7.2. Others
4.5.8. Cardiovascular inflammation
4.5.8.1. Nuclear Medicine
4.5.8.2. Others
4.5.9. Pneumonia
4.5.9.1. Nuclear Medicine
4.5.9.2. Others
4.5.10. Tuberculosis
4.5.10.1. Nuclear Medicine
4.5.10.2. Others
4.5.11. Endocarditis
4.5.11.1. Nuclear Medicine
4.5.11.2. Others
4.5.12. Myocarditis
4.5.12.1. Nuclear Medicine
4.5.12.2. Others
4.5.13. LVAD infection
4.5.13.1. Nuclear Medicine
4.5.13.2. Others
4.5.14. Crohn’s disease
4.5.14.1. Nuclear Medicine
4.5.14.2. Others
4.5.15. Colitis
4.5.15.1. Nuclear Medicine
4.5.15.2. Others
4.5.16. Atherosclerosis
4.5.16.1. Nuclear Medicine
4.5.16.2. Others
4.5.17. Coronary artery disease
4.5.17.1. Nuclear Medicine
4.5.17.2. Others
4.5.18. Organ transplant rejection
4.5.18.1. Nuclear Medicine
4.5.18.2. Others
4.5.19. Others
4.5.19.1. Nuclear Medicine
4.5.19.2. Others
Chapter 5. Others U.S. Infection Imaging Services Market - Competitive Analysis
5.1. Key companies profiled
5.1.1. Rayus Radiology
5.1.1.1. Company Overview
5.1.1.2. Financial Performance
5.1.1.3. Product Benchmarking
5.1.1.4. Strategic Initiatives
5.1.2. CMS Diagnostic Services
5.1.2.1. Company Overview
5.1.2.2. Financial Performance
5.1.2.3. Product Benchmarking
5.1.2.4. Strategic Initiatives
5.1.3. Radnet, Inc
5.1.3.1. Company Overview
5.1.3.2. Financial Performance
5.1.3.3. Product Benchmarking
5.1.3.4. Strategic Initiatives
5.1.4. Dignity Health
5.1.4.1. Company Overview
5.1.4.2. Financial Performance
5.1.4.3. Product Benchmarking
5.1.4.4. Strategic Initiatives
5.1.5. Alliance Medical
5.1.5.1. Company Overview
5.1.5.2. Financial Performance
5.1.5.3. Product Benchmarking
5.1.5.4. Strategic Initiatives
5.1.6. Inhealth Group
5.1.6.1. Company Overview
5.1.6.2. Financial Performance
5.1.6.3. Product Benchmarking
5.1.6.4. Strategic Initiatives
5.1.7. Sonic Healthcare
5.1.7.1. Company Overview
5.1.7.2. Financial Performance
5.1.7.3. Product Benchmarking
5.1.7.4. Strategic Initiatives
5.1.8. Medica Group
5.1.8.1. Company Overview
5.1.8.2. Financial Performance
5.1.8.3. Product Benchmarking
5.1.8.4. Strategic Initiatives
5.1.9. Unilabs
5.1.9.1. Company Overview
5.1.9.2. Financial Performance
5.1.9.3. Product Benchmarking
5.1.9.4. Strategic Initiatives
5.1.10. Simonmed Imaging
5.1.10.1. Company Overview
5.1.10.2. Financial Performance
5.1.10.3. Product Benchmarking
5.1.10.4. Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 U.S. Near Infrared Imaging Market, By Indication, 2018-2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 U.S. infection imaging services market: Market snapshot
Fig. 9 U.S. infection imaging services market: Market segmentation
Fig. 10 U.S. infection imaging services market Strategy framework
Fig. 11 Parent market outlook
Fig. 12 Related/ancillary market outlook
Fig. 13 U.S. infection imaging services market driver impact
Fig. 14 U.S. infection imaging services market restraint impact
Fig. 15 U.S. infection imaging services market porter’s five forces analysis
Fig. 16 U.S. infection imaging services market PESTEL analysis
Fig. 17 U.S. infection imaging services market segment dashboard
Fig. 18 U.S. infection imaging services market: indication movement Analysis
Fig. 19 Fever of unknown origin market estimates and forecast, 2018-2030 (USD Million)
Fig. 20 Orthopedic hardware market estimates and forecast, 2018-2030 (USD Million)
Fig. 21 Musculoskeletal infection market estimates and forecast, 2018-2030 (USD Million)
Fig. 22 Acute appendicitis market estimates and forecast, 2018-2030 (USD Million)
Fig. 23 Osteomyelitis market estimates and forecast, 2018-2030 (USD Million)
Fig. 24 Systemic vasculitis market estimates and forecast, 2018-2030 (USD Million)
Fig. 25 Skin and soft tissue infection market estimates and forecast, 2018-2030 (USD Million)
Fig. 26 Cardiovascular inflammation market estimates and forecast, 2018-2030 (USD Million)
Fig. 27 Pneumonia market estimates and forecast, 2018-2030 (USD Million)
Fig. 28 Tuberculosis market estimates and forecast, 2018-2030 (USD Million)
Fig. 29 Endocarditis market estimates and forecast, 2018-2030 (USD Million)
Fig. 30 Myocarditis market estimates and forecast, 2018-2030 (USD Million)
Fig. 31 LVAD infection market estimates and forecast, 2018-2030 (USD Million)
Fig. 32 Crohn’s disease market estimates and forecast, 2018-2030 (USD Million)
Fig. 33 Colitis market estimates and forecast, 2018-2030 (USD Million)
Fig. 34 Atherosclerosis market estimates and forecast, 2018-2030 (USD Million)
Fig. 35 Coronary artery disease market estimates and forecast, 2018-2030 (USD Million)
Fig. 36 Organ transplant rejection market estimates and forecast, 2018-2030 (USD Million)
Fig. 37 Others market estimates and forecast, 2018-2030 (USD Million)
Companies Mentioned
- Rayus Radiology
- Cms Diagnostic Services
- Radnet, Inc
- Dignity Health
- Alliance Medical
- Inhealth Group
- Sonic Healthcare
- Medica Group
- Unilabs
- Simonmed Imaging
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 102 |
| Published | October 2022 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 30.76 Billion |
| Forecasted Market Value ( USD | $ 42.99 Billion |
| Compound Annual Growth Rate | 4.3% |
| Regions Covered | United States |
| No. of Companies Mentioned | 10 |
